X4 Pharmaceuticals $150M Debt Financing with K2 HealthVentures LLC
X4 Pharmaceuticals entered into a $150 million senior secured term loan facility with K2 HealthVentures, consisting of an immediate $80 million tranche and an additional $70 million available upon request and lender approval. The proceeds were used to repay an existing $75 million loan from Hercules and will support the potential commercial launch of mavorixafor. The new facility features a 48-month maturity and an interest-only period through at least October 2029.
- Value
- $150M
- Counterparty
- K2 HealthVentures LLC
- Term
- 4 years